Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872623 | 1.00 | HSD11B1 (0.84) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL1322140 | 1.00 | HSD11B1 (0.84) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL1322141 | 1.00 | HSD11B1 (0.84) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL349950 | 0.93 | HSD11B1 (0.79) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL349949 | 0.93 | HSD11B1 (0.79) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL351523 | 0.93 | HSD11B1 (0.79) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL351524 | 0.93 | HSD11B1 (0.79) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL350476 | 0.91 | HSD11B1 (1.00) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL350958 | 0.91 | HSD11B1 (1.00) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL350558 | 0.89 | HSD11B1 (0.88) | HSD11B1CYP2D6NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | claimed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | claimed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | claimed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | claimed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | claimed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885NPY5R 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.